Zero-fluoroscopy Approach Versus Fluoroscopic Approach for the Ablation of Paroxysmal Supraventricular Tachycardia
NCT ID: NCT03042078
Last Updated: 2023-11-24
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
3060 participants
INTERVENTIONAL
2012-01-31
2018-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
PARALLEL
TREATMENT
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Zero-fluoroscopic ablation
Paroxysmal supraventricular tachycardia will be ablated under the guidance of Ensite NavX and without the use of fluoroscopy.
Zero-fluoroscopic ablation
Catheter ablation will be performed under the guidance of Ensite NavX and without the use of fluoroscopy.
Conventional fluoroscopic ablation
Paroxysmal supraventricular tachycardia will be ablated under the guidance of Ensite NavX plus fluoroscopy.
Conventional fluoroscopic ablation
Catheter ablation will be performed under the guidance of Ensite NavX plus fluoroscopy.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Zero-fluoroscopic ablation
Catheter ablation will be performed under the guidance of Ensite NavX and without the use of fluoroscopy.
Conventional fluoroscopic ablation
Catheter ablation will be performed under the guidance of Ensite NavX plus fluoroscopy.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Atrioventricular Reentrant Tachycardia
Exclusion Criteria
* Organic supraventricular tachycardia
12 Years
90 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Chinese Academy of Medical Sciences, Fuwai Hospital
OTHER
First Affiliated Hospital, Sun Yat-Sen University
OTHER
Xiangyang Central Hospital
OTHER
First Affiliated Hospital of Guangxi Medical University
OTHER
Guangdong Provincial People's Hospital
OTHER
Morristown Memorial Hospital
OTHER
Beijing Anzhen Hospital
OTHER
Ningbo No. 1 Hospital
OTHER
Tongji Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Yan Wang
Professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Yan Wang, PhD
Role: PRINCIPAL_INVESTIGATOR
Tongji Hospital Wuhan, Hubei China
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Tongji Hospital
Wuhan, Hubei, China
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Anselmino M, Sillano D, Casolati D, Ferraris F, Scaglione M, Gaita F. A new electrophysiology era: zero fluoroscopy. J Cardiovasc Med (Hagerstown). 2013 Mar;14(3):221-7. doi: 10.2459/JCM.0b013e3283536555.
Mobinizadeh M, Arabloo J, Hamouzadeh P, Akbari Sari A. A systematic review of the effectiveness of catheter ablation NavX mapping system for treatment of the cardiac arrhythmia. Med J Islam Repub Iran. 2015 Mar 10;29:189. eCollection 2015.
Wang Y, Patel D, Wang DW, Yan JT, Hsia HH, Liu H, Zhao CX, Zuo HJ, Wang DW. beta1-Adrenoceptor blocker aggravated ventricular arrhythmia. Pacing Clin Electrophysiol. 2013 Nov;36(11):1348-56. doi: 10.1111/pace.12196. Epub 2013 Jun 10.
Lim PB, Robb D, Lambiase PD. Electrophysiology and ablation of arrhythmias. Br J Hosp Med (Lond). 2012 Jun;73(6):312-8. doi: 10.12968/hmed.2012.73.6.312.
Brown KR, Rzucidlo E. Acute and chronic radiation injury. J Vasc Surg. 2011 Jan;53(1 Suppl):15S-21S. doi: 10.1016/j.jvs.2010.06.175. Epub 2010 Sep 16.
Chen G, Wang Y, Proietti R, Wang X, Ouyang F, Ma CS, Yu RH, Zhao C, Ma K, Qiu J, Liu Q, Wang DW. Zero-fluoroscopy approach for ablation of supraventricular tachycardia using the Ensite NavX system: a multicenter experience. BMC Cardiovasc Disord. 2020 Feb 3;20(1):48. doi: 10.1186/s12872-020-01344-0.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
TJHCDD-ZF-PSVT-20140301
Identifier Type: -
Identifier Source: org_study_id